Heron Therapeutics shares jump 14.81% premarket as ZYNRELEF and APONVIE drive 65% Acute Care growth and 2026 revenue guidance of $173–$183M.

Heron Therapeutics (HRTX) surged 14.81% in premarket trading following the release of robust fourth-quarter and full-year 2025 financial results, which highlighted a 65.1% year-over-year revenue growth in its Acute Care franchise driven by ZYNRELEF and APONVIE. The company reported $154.9 million in 2025 net revenue and provided 2026 guidance of $173–$183 million in revenue and $10–$20 million in adjusted EBITDA. Key catalysts included CMS approval of product-specific J-Codes for ZYNRELEF and APONVIE, enhancing reimbursement clarity, and strategic initiatives like distributor incentives and a completed Vial Access Needle transition. The CEO emphasized momentum in 2026, citing improved commercial execution and market adoption. These developments, coupled with strong Q4 performance despite oncology segment declines, fueled investor optimism about future revenue expansion.